-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Amgen, Raises Price Target to $400

Benzinga·08/05/2026 15:37:29
Listen to the news
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $370 to $400.